FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2653 June 23, 2005 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: In late 2004, a "boxed warning" was added to the labeling for promethazine hydrochloride (Phenergan), including a contraindication for use in children less than two years of age and a strengthened warning with regard to use in children two years of age or older. We describe the basis for this action.

Promethazine is widely used in children as an antihistamine, antiemetic, and sedative. Since its approval in 1951, serious and often life-threatening adverse events, including respiratory depression, oversedation, agitation, hallucinations, seizures, and dystonic reactions, have been reported with promethazine use in children.^1,2 The occurrence of these adverse . . . [Full Text of this Article]

This article has been cited by other articles:

• Haas, H. L., Sergeeva, O. A., Selbach, O. (2008). Histamine in the Nervous System. Physiol. Rev. 88: 1183-1241 [Abstract] [Full Text]  
• Wood, G. J., Shega, J. W., Lynch, B., Von Roenn, J. H. (2007). Management of Intractable Nausea and Vomiting in Patients at the End of Life: "I Was Feeling Nauseous All of the Time . . . Nothing Was Working". JAMA 298: 1196-1207 [Abstract] [Full Text]  
• Simons, F. E. R. (2007). Diphenhydramine in Infants. Arch Pediatr Adolesc Med 161: 105-105 [Full Text]